# WANTAI SARS-CoV-2 RT-PCR

*Developing Scientifically*

*Focusing on the Health*

## *COVID-19*




For more information:
wtexport@ystwt.com

Add: 31 Kexueyuan Rd. changping, Beijing, China E-mail: wtexport@ystwt.com Tel: +86 (10) 59528888 Web: ww.ystwt.cn

This kit is intended for qualitative detection of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 ) RNA extracted from oropharyngeal swab, nasopharyngeal swab, sputum, endotracheal aspirate and bronchoalveolar lavage fluid samples of patients suspected for infection with COVID-19.

| | | | |
|---|---|---|---|
| **Kit Components** | RT-PCR master mix | 1.25mL×1 | dNTPs, rTth enzyme, UDG enzyme |
| | Mn(OAc)2 | 125μL×1 | Mn(OAc)2 solution |
| | Primer and probe | 125μL×1 | Primer and probe solution |
| | Positive control | 1 mL×1 | Artificial virus containing SARS-CoV-2 amplification target sequence |
| | Negative control | 1 mL×1 | Saline diluted negative oropharyngeal swab |







**Features**

- ORF1ab and N genes
- Human β-actin as internal control
- Ct cut-off: ≤40
- LoD: 50copies/ml
- Throat swab or bronchoalveolar lavage samples
- Compatible with BIO-RAD CFX96, ABI 7500, Roche, Qiagen PCR instruments
- Reagents stable for 12 months at -15℃

**Performance Validation**: FIND conducted independent evaluation at the University Hospitals of Geneva (HUG) to verify the limit of detection (LOD) and the clinical performance of the kit. The LOD analysis was performed using cultured viral stocks from a clinical isolate from Switzerland that was quantified using an E gene standard.

**Results**: Lod (copies/reaction): 1-10; Avg Ct (lowest dilution 10/10) ORF1ab:36.20, N: 37.12; clinical sensitivity (50 positives): 100% (95%CI: 93, 100), clinical specificity (100 negatives): 100%(95%CI: 96, 100)